Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Master Protocol for an Exploratory, Phase 2a, Proof-of-Concept Platform Study to Evaluate the Safety, Tolerability, and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis

NCT07294170 is registered in ClinicalTrials.gov with argenx as lead sponsor.

NCT NCT07294170
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07294170 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Master Protocol for an Exploratory, Phase 2a, Proof-of-Concept Platform Study to Evaluate the Safety, Tolerability, and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
Lead sponsor
argenx
Phase
Observational
Overall status
Recruiting
Start date
December 19, 2025
Completion date
March 7, 2028
Enrollment
70 (estimated)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

achr-ab seropositive generalized myasthenia gravis, generalized myasthenia gravis, generalized myasthenia gravis (gmg), gmg, mg, myasthenia gravis